Loading
Sarcoma surgeon who led the ISG-STS 1001 trial of histology-tailored neoadjuvant chemotherapy.
Alessandro Gronchi is Chair of the Sarcoma Service at the Fondazione IRCCS Istituto Nazionale dei Tumori in Milan, a surgeon whose specialisms are sarcoma surgery, retroperitoneal sarcoma and neoadjuvant chemotherapy. He is known for chairing ISG-STS 1001, the randomised trial that compared histology-tailored neoadjuvant chemotherapy with standard chemotherapy in high-risk soft-tissue sarcoma, and STRASS, which tested preoperative radiotherapy. His Lancet Oncology paper on ISG-STS 1001 set out how tailoring chemotherapy to sarcoma histotype compares with a standard regimen. He continues to lead the sarcoma surgical programme at INT Milan, with his publications listed on PubMed.
| Title | Journal | Year |
|---|---|---|
| Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001) | Lancet Oncology | 2017 |
Shares ISG-STS 1001, Fondazione IRCCS Istituto Nazionale dei Tumori, Sarcomas (soft tissue, bone, GIST).
Shares ISG-STS 1001, A same-week expert second opinion for every rare cancer diagnosis, Sarcomas (soft tissue, bone, GIST).
Shares Fondazione IRCCS Istituto Nazionale dei Tumori, A same-week expert second opinion for every rare cancer diagnosis.
Shares Fondazione IRCCS Istituto Nazionale dei Tumori, Sarcomas (soft tissue, bone, GIST).
Shares A same-week expert second opinion for every rare cancer diagnosis, Sarcomas (soft tissue, bone, GIST).
Shares European Society of Surgical Oncology, Sarcomas (soft tissue, bone, GIST).